Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Pediatric melanoma: analysis of an international registry.

Averbook BJ, Lee SJ, Delman KA, Gow KW, Zager JS, Sondak VK, Messina JL, Sabel MS, Pittelkow MR, Ecker PM, Markovic SN, Swetter SM, Leachman SA, Testori A, Curiel-Lewandrowski C, Go RS, Jukic DM, Kirkwood JM.

Cancer. 2013 Nov 15;119(22):4012-9. doi: 10.1002/cncr.28289. Epub 2013 Sep 10.

2.

Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.

Wagner JD, Ranieri J, Evdokimow DZ, Logan T, Chuang TY, Johnson CS, Jung SH, Wenck S, Coleman JJ 3rd.

Plast Reconstr Surg. 2003 Aug;112(2):486-97.

PMID:
12900606
3.
4.

Is sentinel lymph node biopsy of therapeutic relevance for melanoma?

Möhrle M, Schippert W, Rassner G, Garbe C, Breuninger H.

Dermatology. 2004;209(1):5-13. Erratum in: Dermatology. 2005;210(1):84.

PMID:
15237261
5.

Melanoma in children and the use of sentinel lymph node biopsy.

Bütter A, Hui T, Chapdelaine J, Beaunoyer M, Flageole H, Bouchard S.

J Pediatr Surg. 2005 May;40(5):797-800.

PMID:
15937817
6.

Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.

Naffouje S, Naffouje R, Bhagwandin S, Salti GI.

Melanoma Res. 2015 Dec;25(6):496-502. doi: 10.1097/CMR.0000000000000195.

PMID:
26317170
7.

The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.

Statius Muller MG, van Leeuwen PA, de Lange-De Klerk ES, van Diest PJ, Pijpers R, Ferwerda CC, Vuylsteke RJ, Meijer S.

Cancer. 2001 Jun 15;91(12):2401-8.

PMID:
11413531
8.

Diversity of stage III melanoma in the era of sentinel lymph node biopsy.

Egger ME, Callender GG, McMasters KM, Ross MI, Martin RC 2nd, Edwards MJ, Urist MM, Noyes RD, Sussman JJ, Reintgen DS, Stromberg AJ, Scoggins CR.

Ann Surg Oncol. 2013 Mar;20(3):956-63. doi: 10.1245/s10434-012-2701-z. Epub 2012 Oct 14.

PMID:
23064795
9.

Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.

Kyrgidis A, Tzellos T, Mocellin S, Apalla Z, Lallas A, Pilati P, Stratigos A.

Cochrane Database Syst Rev. 2015 May 16;(5):CD010307. doi: 10.1002/14651858.CD010307.pub2. Review.

PMID:
25978975
10.

Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.

Han D, Zager JS, Shyr Y, Chen H, Berry LD, Iyengar S, Djulbegovic M, Weber JL, Marzban SS, Sondak VK, Messina JL, Vetto JT, White RL, Pockaj B, Mozzillo N, Charney KJ, Avisar E, Krouse R, Kashani-Sabet M, Leong SP.

J Clin Oncol. 2013 Dec 10;31(35):4387-93. doi: 10.1200/JCO.2013.50.1114. Epub 2013 Nov 4.

PMID:
24190111
11.

Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.

Murali R, Haydu LE, Quinn MJ, Saw RP, Shannon K, Spillane AJ, Stretch JR, Thompson JF, Scolyer RA.

Ann Surg. 2012 Jan;255(1):128-33. doi: 10.1097/SLA.0b013e3182306c72.

PMID:
21975320
12.

Is head and neck melanoma different from trunk and extremity melanomas with respect to sentinel lymph node status and clinical outcome?

Fadaki N, Li R, Parrett B, Sanders G, Thummala S, Martineau L, Cardona-Huerta S, Miranda S, Cheng ST, Miller JR 3rd, Singer M, Cleaver JE, Kashani-Sabet M, Leong SP.

Ann Surg Oncol. 2013 Sep;20(9):3089-97. doi: 10.1245/s10434-013-2977-7. Epub 2013 May 7.

PMID:
23649930
13.

Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.

Cherpelis BS, Haddad F, Messina J, Cantor AB, Fitzmorris K, Reintgen DS, Fenske NA, Glass LF.

J Am Acad Dermatol. 2001 May;44(5):762-6.

PMID:
11312421
14.

Clinicopathologic and survival differences between upper and lower extremity melanomas.

Egger ME, Tabler BL, Dunki-Jacobs EM, Callender GG, Scoggins CR, Martin RC 2nd, Quillo AR, Stromberg AJ, McMasters KM.

Am Surg. 2012 Jul;78(7):779-87.

PMID:
22748538
15.

Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes.

Egger ME, Bhutiani N, Farmer RW, Stromberg AJ, Martin RC 2nd, Quillo AR, McMasters KM, Scoggins CR.

Surgery. 2016 May;159(5):1412-21. doi: 10.1016/j.surg.2015.12.002. Epub 2016 Jan 8.

PMID:
26775577
16.

Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?

Gajdos C, Griffith KA, Wong SL, Johnson TM, Chang AE, Cimmino VM, Lowe L, Bradford CR, Rees RS, Sabel MS.

Cancer. 2009 Dec 15;115(24):5752-60. doi: 10.1002/cncr.24660.

17.

Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than four millimeters.

Caracò C, Celentano E, Lastoria S, Botti G, Ascierto PA, Mozzillo N.

Ann Surg Oncol. 2004 Mar;11(3 Suppl):198S-202S.

PMID:
15023751
18.

Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary?

Nahabedian MY, Tufaro AP, Manson PN.

Ann Plast Surg. 2003 Jun;50(6):601-6.

PMID:
12783009
19.

Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes.

Zogakis TG, Essner R, Wang HJ, Foshag LJ, Morton DL.

Ann Surg Oncol. 2007 May;14(5):1604-11. Epub 2007 Mar 1.

PMID:
17333418
20.

Sarcopenia as a prognostic factor among patients with stage III melanoma.

Sabel MS, Lee J, Cai S, Englesbe MJ, Holcombe S, Wang S.

Ann Surg Oncol. 2011 Dec;18(13):3579-85. doi: 10.1245/s10434-011-1976-9. Epub 2011 Aug 6.

PMID:
21822551

Supplemental Content

Support Center